An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the treating physician.
Swollen Joint Count (SJC) \>= 3 of 28 joints of the Disease Activity Score (DAS)28.
Measurement of C-Reactive Protein (CRP)-level at Baseline (BL) or \<= 4 weeks prior to BL at a timepoint when the Prednisolone equivalent dose of Glucocorticoid treatment was \<= 10 mg/day for at least 7 days.
Upadacitinib treatment is indicated as per local Summary of Product characteristics (SmPC).
Decision on the treatment with Upadacitinib was made prior to any decision to approach the patient to participate in this study.
You may not be if
Participants who cannot be treated with Upadacitinib according to the local Upadacitinib SmPC.
Prior treatment with Upadacitinib.
Treatment with Sarilumab or Tocilizumab within the last 8 weeks before the CRP level for inclusion was measured.
Participants currently participating in interventional research.
Participants who are unwilling or unable to complete the patient reported questionnaires.
Clareo Health | An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis
